



CERTIFICATE OF MAILING

I hereby certify that this paper is being deposited with the U.S. Postal Service as first class mail on the date indicated below in an envelope addressed to: Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450.

Name of Person Mailing: CHRIS MYERS

Signature: Chris Myers Date: March 15, 2004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Information Disclosure Statement Address to: Commissioner of Patents PO Box 1450 Alexandria, VA 22313-1450	First Named Inventor	Joseph Armstrong Martin
	Application Number	10/717,260
	Filing Date	November 19, 2003
	Group Art Unit	1614
	Examiner	
	Attorney Docket No.	R0150C-REG
	Title	Antiviral Nucleoside Derivatives

Sir:

Transmittal for Information Disclosure Statement

Transmitted herewith for filing in the above-entitled patent application is an Information Disclosure Statement, in compliance with 37 CFR §1.56, which may be material to the patentability of the subject patent application.

[X] Attached are:

- Form 1449, "List of References Cited," with copies of references B1 thru B10 and C1 thru C12 (copies of U.S. patents not included)
- Return postcard

[X] The Information Disclosure Statement is being submitted (a) within three months of the filing date, or (b) before the mailing date of the first Office Action. **Therefore, no fee is due under 37 CFR 1.97(b).**

[X] Applicants believe that no fees are due. However, should this not be the case, the Commissioner is hereby authorized to charge any additional fees that may be required to Deposit Account No. 18-1700.



USPN 10/717,260

Attorney Docket No. R0150C-REG

The Examiner is respectfully requested to consider these documents and to make them of record in the subject application.

Respectfully submitted,


Brian L. Buckwalter

Reg. No. 46,585

Agent for Applicants

Roche Palo Alto LLC
Patent Law Dept. M/S A2-250
3431 Hillview Avenue
Palo Alto, CA 94304
Direct Phone (650) 855-6995

Date: March 15, 2004



Page 1 of 2	INFORMATION DISCLOSURE STATEMENT BY APPLICANT(S)	ATTY. DOCKET NO. R0150C-REG	SERIAL NO. 10/717,260
	FIRST NAMED INVENTOR Joseph Armstrong Martin		
	FILING DATE November 19, 2003	ART UNIT unknown	

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
	A1	3,998,807		John G. Moffatt	12-21-1976	
	A2	4,957,924		Lilia M. Beauchamp	09-18-1990	
	A3	5,216,142		Horrobin, et al.	06-01-1993	
	A4	6,184,376		Leanna, et al.	02-06-2001	

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ₆
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
	B1	WO	02/100415	A2	F. Hoffmann-La Roche (CH)	12-19-2002		
	B2	WO	01/45509	A1	ICN Pharmaceuticals, (US)	06-28-2001		
	B3	WO	01/68034	A2	ICN Pharmaceuticals (US)	09-20-2001		
	B4	WO	01/90121	A2	Novirio Pharmaceuticals, Ltd. Et al. (US),(IT)	11-29-2001		
	B5	WO	00/23454	A1	Schering Corp. (US)	04-27-2000		
	B6	WO	94/22887	A1	Norsk Hydro A.S. (NO)	10-13-1994		
	B7	WO	94/24134	A1	Hoechst AG (DE)	10-27-1994		
	B8	WO	93/07163	A1	Norsk Hydro A.S. (NO)	04-15-1993		
	B9	EP	0 375 329	B1	The Wellcome Foundation Ltd.(GB)	06-27-1990		
	B10	EP	0 343 133	B1	Medivir Aktiebolag (SE)	11-23-1989		

Examiner Signature		Date Considered	
-------------------------------	--	----------------------------	--

INFORMATION DISCLOSURE STATEMENT BY APPLICANT(S) Page 2 of 2	ATTY. DOCKET NO. R0150C-REG	SERIAL NO. 10/717,260
	FIRST NAMED INVENTOR Joseph Armstrong Martin	
	FILING DATE November 19, 2003	ART UNIT unknown

THE PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C1	BALIMANE, et al., "Direct Evidence for Peptide Transporter (PEPT1)-Mediated Uptake of a Nonpeptide Prodrug, Valacyclovir," Biochemical and Biophysical Research Communications, (1998) pp. 246-251, vol. 250, Article No. RC989298	
	C2	BEAUCHAMP, et al., "Amino Acid Ester Prodrugs of Acyclovir," Antiviral Chemistry & Chemotherapy, (1992), pp. 157-164, 3(3)	
	C3	CHAMBERLAIN, et al., "2'-Ester Prodrugs of the Varicella-Zoster Antiviral Agent, 6-Methoxypurine Arabinoside," Antiviral Chemistry & Chemotherapy, (1992), pp. 371-378, 3(6)	
	C4	HARDEN, et al., "Prodrugs of the Selective Antiherpovirus Agent 9-[4-Hydroxy-3-(hydroxymethyl)but-1-yl]guanine (BRL 39123) with Improved Gastrointestinal Absorption Properties," J. Med. Chem., (1989), pp 1738-1743, 32	
	C5	HODGE, et al., "Selection of an Oral Prodrug (BRL 42810; Famciclovir) for the Antiherpovirus Agent BRL 39123 [9-4(-Hydroxy-3-Hydroxymethylbut-1-yl)Guanine; Penciclovir]," Antimicrobial Agents and Chemotherapy, (1989), pp. 1765-1773, 33(10).	
	C6	JONES, et al. "Di- and Triester Prodrugs of the Varicella-Zoster Antiviral Agent 6-Methoxypurine Arabinoside," J. Med. Chem., (1992), pp. 56-63, 35.	
	C7	KIM, et al., "Synthesis and Evaluation of 2-Amino-9-(1,3-dihydroxy-2-propoxymethyl)-6-fluoropurine Mono- and Diesters as Potential Prodrugs of Ganciclovir," J. Med. Chem., (1999), pp. 324-328, 42.	
	C8	MAAG, Hans et al., "Synthesis and Anti-HIV Activity of 4'-Azido- and 4'-Methoxynucleosides," J. Med. Chem., (1992), pp. 1440-1451, 35	
	C9	MOFFATT, J.G., "Chemical Transformations of the Sugar Moiety of Nucleosides", Nucleoside Analogues, (R. T. Walker, E. De Clercq, & F. Eckstein, eds.), (1979), pp. 71-164, Plenum Press, New York. (see p. 144)	
	C10	NIELSEN, et al., "Human Peptide Transporters: Therapeutic Applications," Expert Opinion, Ther. Patents (2002), pp. 1329-1350, 12(9), Ashley Publications	
	C11	PUE, et al., "Pharmacokinetics of Famciclovir in Man," Antiviral Chemistry & Chemotherapy, (1993), pp. 47-55, 4, Suppl. 1	
	C12	RUBIO-ALIAGA, et al., "Mammalian Peptide Transporters as Targets for Drug Delivery," Trends in Pharmacological Sciences, (2002), pp. 434-440, 23(9)	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

I. *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

I. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

124028